Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: A randomized, placebo-controlled, double-blind, parallel clinical trial

Dermatologic Therapy

Volumn 28, Issue 1, 2015, Pages 44-51

  Jin, Sang Yoon ^a   Lim, Won Suk ^a   Sung, Nam Hee ^a   Cheong, Kyung Ah ^a   Lee, Ai Young ^a,b  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

atopic dermatitis; CCL17; combination; glucosamine; low dose cyclosporine; SCORAD

Indexed keywords

CYCLOSPORIN; GLUCOSAMINE SULFATE; INTERLEUKIN 31; PLACEBO; THYMUS AND ACTIVATION REGULATED CHEMOKINE; CCL17 PROTEIN, HUMAN; DERMATOLOGICAL AGENT; GLUCOSAMINE; IL31 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ARTICLE; ATOPIC DERMATITIS; CHICKENPOX; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LOW DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DERMATITIS, ATOPIC; DRUG COMBINATION; EOSINOPHIL; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHEMOKINE CCL17; CHILD; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; GLUCOSAMINE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920885483     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12163     Document Type: Article

References (40)

1. Schmitt J, Schmitt N, Meurer M,. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007: 21: 606-619.
2. Schmitt J, Schakel K, Schmitt N, Meurer M,. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007: 87: 100-111.
3. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000: 142: 52-58.
4. Gelbard CM, Hebert AA,. New and emerging trends in the treatment of atopic dermatitis. Patient Prefer Adherence 2008: 2: 387-392.
5. Ricci G, Dondi A, Patrizi A, Masi M,. Systemic therapy of atopic dermatitis in children. Drugs 2009: 69: 297-306.
6. Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, de Bruin-Weller MS,. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007: 21: 85-89.
7. Faulds D, Goa KL, Benfield P,. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993: 45: 953-1040.
8. Munro CS, Levell NJ, Shuster S, Friedmann PS,. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994: 130 (3): 376-380.
9. Sepp N, Fritsch PO,. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol 1993: 128: 213-216.
10. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY,. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009: 273: 243-249.
11. Setnikar I,. Antireactive properties of "chondroprotective" drugs. Int J Tissue React 1992: 14: 253-261.
12. Henrotin Y, Lambert C, Richette P,. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. Semin Arthritis Rheum 2014: 43: 579-587.
13. Elli L, Ciulla MM, Busca G, et al. Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease. Lab Invest 2011: 91: 452-461.
14. Song KH, Kang JH, Woo JK, et al. The novel IGF-IR/Akt-dependent anticancer activities of glucosamine. BMC Cancer 2014: 14: 31.
15. Chen NH, Cheong KA, Kim CH, Noh M, Lee AY,. Glucosamine induces activated T cell apoptosis through reduced TCR. Scand J Immunol 2013: 78: 17-27.
16. Kim CH, Cheong KA, Park CD, Lee AY,. Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development. Scand J Immunol 2011: 73: 536-545.
17. Kuo CT, Leiden JM,. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol 1999: 17: 149-187.
18. Ballard DW,. Molecular mechanisms in lymphocyte activation and growth. Immunol Res 2001: 23: 157-166.
19. Kim CH, Choi YS, Cheong KA, Lee AY,. Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Int Immunopharmacol 2013: 15: 424-432.
20. Kwon HB, Ahn BJ, Choi Y, et al. Combination of glucosamine improved therapeutic effect of low dose cyclosporine A in patients with atopic dermatitis: a pilot study. J Dermatol 2013: 40 (3): 207-210.
21. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J,. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012: 67: 99-106.
22. Schmitt J, Langan S, Deckert S, et al. Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013: 132: 1337-1347.
23. Flohr C,. Atopic dermatitis diagnostic criteria and outcome measures for clinical trials: still a mess. J Invest Dermatol 2011: 131: 557-559.
24. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001: 107: 535-541.
25. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A,. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005: 60: 685-688.
26. Kwon YS, Oh SH, Wu WH, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. Exp Dermatol 2010: 19: 246-251.
27. Furue M, Matsumoto T, Yamamoto T, et al. Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis. J Dermatol Sci 2012: 66: 60-63.
28. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S,. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005: 516: 180-181.
29. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006: 118: 930-937.
30. Schulz F, Marenholz I, Fölster-Holst R, et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007: 120: 1097-1102.
31. Incorvaia C, Frati F, Verna N, D'Alò S, Motolese A, Pucci S,. Allergy and the skin. Clin Exp Immunol 2008: 153 (Suppl. 1): 27-29.
32. Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB,. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol 2013: 132: 446-454.
33. Ezzat MH, Hasan ZE, Shaheen KY,. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011: 25: 334-339.
34. Nobbe S, Dziunycz P, Mühleisen B, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol 2012: 92: 24-28.
35. Raap U, Weißmantel S, Gehring M, Eisenberg AM, Kapp A, Fölster-Holst R,. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol 2012: 23: 285-288.
36. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980: 92: 44-47.
37. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A,. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997: 195: 10-19.
38. Czech W, Brautigam M, Weidinger G, Schopf E,. A bodyweight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000: 42: 653-659.
39. Berth-Jones J, Graham-Brown RA, Marks R, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997: 136: 76-81.
40. Nakamura S, Takeda K, Hashimoto Y, et al. Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. J Dermatolog Treat 2012: 23: 112-115.